Compugen (NASDAQ:CGEN) Stock Rating Upgraded by BidaskClub

Compugen (NASDAQ:CGEN) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, BidAskClub reports.

Several other brokerages have also weighed in on CGEN. Jefferies Financial Group restated a “buy” rating and issued a $20.00 price objective on shares of Compugen in a report on Tuesday, August 11th. SVB Leerink upped their target price on shares of Compugen from $15.00 to $19.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. ValuEngine cut shares of Compugen from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Oppenheimer assumed coverage on shares of Compugen in a report on Thursday, July 30th. They issued a “buy” rating and a $19.00 price target for the company. Finally, Zacks Investment Research downgraded Compugen from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Compugen currently has an average rating of “Buy” and an average price target of $19.56.

CGEN stock opened at $18.86 on Friday. Compugen has a twelve month low of $3.83 and a twelve month high of $19.90. The company has a market cap of $1.29 billion, a P/E ratio of -49.63 and a beta of 2.73. The business has a fifty day moving average of $16.70 and a 200-day moving average of $13.70.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.02. On average, analysts predict that Compugen will post -0.37 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Compugen in the 1st quarter valued at about $80,000. Philadelphia Trust Co. bought a new stake in Compugen in the 1st quarter valued at approximately $109,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Compugen in the 2nd quarter valued at approximately $135,000. SG Americas Securities LLC acquired a new position in Compugen during the 2nd quarter worth approximately $150,000. Finally, ProShare Advisors LLC bought a new position in shares of Compugen during the 2nd quarter worth approximately $183,000. 57.43% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Further Reading: Understanding Analyst Ratings

Analyst Recommendations for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.